Dry Powder Inhaler Market Outlook 2024: Exclusive Report By The Business Research Company | Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company , Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Sun Pharmaceutical

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2103

The Business Research Company offers in-depth market insights through Dry Powder Inhaler Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The dry powder inhaler market size has grown strongly in recent years. It will grow from $20.18 billion in 2023 to $21.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.

The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $25.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13430&type=smp

Market Segmentation:
The main types of products in dry powder inhalers are single-dose inhalers and multi-dose inhalers. A single-dose inhaler refers to a dry powder inhalation device that administers medication directly to the lungs. It performs various functions, such as manually operated inhaler devices and digitally operated inhaler devices and used in a variety of applications such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others. It also includes a variety of end-users, including hospitals and clinics, homecare settings, ambulatory surgical centers and others.

Major Driver - Rising Prevalence Of Respiratory Diseases Fuels Growth In The Dry Powder Inhaler Market
The growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market going forward. Respiratory diseases refer to respiratory disorders or lung diseases, encompassing a broad category of medical conditions affecting the respiratory system. Dry powder inhalers are essential in treating respiratory conditions such as asthma, COPD, and cystic fibrosis as they deliver medicine directly to the lungs, where it is most effective. It is a promising alternative to traditional drug delivery methods for respiratory diseases. For instance, in June 2023, according to reports published by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Therefore, the growing prevalence of respiratory diseases will drive the growth of the dry powder inhaler market.

Competitive Landscape:
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company , Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd, Beximco Pharmaceuticals Ltd, Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals , Presspart Manufacturing Ltd, SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report

Top Trend - Innovative Products And Market Expansion Strategies In The Dry Powder Inhaler (DPI) Market
Major companies operating in the dry powder inhaler market are developing innovative products with muscarinic antagonist for treating chronic obstructive pulmonary disease (COPD) and expanding their product portfolio. A muscarinic antagonist is a drug that inhibits the muscarinic acetylcholine receptor. It controls and treats various illnesses, such as COPD and organophosphate poisoning. For instance, in June 2021, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched Tiogiva, a long-acting muscarinic antagonist dry powder inhaler (DPI) that is used to treat chronic obstructive pulmonary disease (COPD) in the UK. It is the bioequivalent generic version of Boehringer-Ingelheim's Spiriva Handihaler. It functions by calming the muscles in the airways, which facilitates breathing. It is taken once a day and is indicated for the long-term maintenance treatment of COPD in adults. Moreover, it is easy to use and does not require a spacer.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Dry Powder Inhaler Market Characteristics
3. Dry Powder Inhaler Market Trends And Strategies
4. Dry Powder Inhaler Market - Macro Economic Scenario
5. Dry Powder Inhaler Market Size And Growth
…..
27. Dry Powder Inhaler Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.